Business Development Manager Appointed

RNS Number : 5270B

Tissue Regenix Group PLC

21 February 2011

 



Tissue Regenix Appoints Adrian Ford as Business Development Manager

YORK, 21 February, 2011 - Tissue Regenix, the RegenMed company focused on the development and commercialisation of acellular tissue replacement products to address the chronic global shortfalls in donor tissue availability, today announced the appointment of Adrian Ford as Business Development Manager. Adrian will be responsible for the sales and marketing development of Tissue Regenix's range of acellular tissue replacement products, manufactured using the proprietary dCELL^® technology platform.

Adrian has over 20 years of sales and marketing experience in the heath care and medical devices sector, most recently as head of consultancy group, Response Orthopedics, advising organizations on the development of full line strategic plans for main line trauma and external fixator systems.

Prior to Response Orthopedics, Adrian held a number of senior business development roles at Biomet UK, latterly as International Sales and Marketing Director of the BTBS divisions (Biomet Trauma & Biomet Spine), a position he held from October 2007 to January 2010. During this time Adrian acquired extensive experience in overseeing international sales and marketing programmes, growing and managing sales channels, developing and managing KOL advisory boards and implementing launch plans and pricing strategies.

Before joining Biomet Adrian held positions at Merck, Biotrace Ltd., ConvaTec Ltd., DePuy (J&J) Trauma Division and OthoSolutions Ltd.

Adrian holds a HNC in Applied Biology from the South Glamorgan Institute of Higher Education and a BSc (Hons) in Applied Biological Sciences from the University of the West of England.

Enquiries:

Financial Dynamics   Ben Atwell / John Dineen	[phone]
Tissue Regenix Group plc Antony Odell	[phone]
Peel Hunt LLP (Nominated Adviser) James Steel / Vijay Barathan	[phone]

About Tissue Regenix

Tissue Regenix, the RegenMed Company, was incorporated in May 2006 to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher from the University of Leeds in the field of tissue decellularisation. Its dCELL® Technology comprises a patented process which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts.

About dCELL^® Technology

The process comprised within the dCELL^® Technology involves the production of biological scaffolds created by taking a piece of human or animal tissue that is equivalent to the diseased or damaged body part which is being replaced, treating such tissue with a series of gentle chemical washes and then sterilising it. The end product is a scaffold which can be stored under normal conditions at room temperature like any synthetic medical device and, when it is implanted into the body, it repopulates with the patient's own cells using natural biological repair mechanisms.

Tissue Regenix's strategy is to continue to use its core dCELL^® Technology as a platform to develop a range of products using the established medical device regulatory pathway to deliver solutions to unmet clinical needs. The three priority markets for the application of the technology are: Vascular (e.g. Vascular Patches); Cardiac (e.g. Heart Valves); and Orthopaedics (e.g. Meniscus).

 

END

 

 

NRAGGUBCPUPGGQR